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C-type lectin receptors (CLRs) are essential for multicellular existence, having diverse
functions ranging from embryonic development to immune function. One subgroup of
CLRs is the Dectin-1 cluster, comprising of seven receptors including MICL, CLEC-2, CLEC-
12B, CLEC-9A, MelLec, Dectin-1, and LOX-1. Reflecting the larger CLR family, the Dectin-
1 cluster of receptors has a broad range of ligands and functions, but importantly, is
involved in numerous pathophysiological processes that regulate health and disease.
Indeed, these receptors have been implicated in development, infection, regulation of
inflammation, allergy, transplantation tolerance, cancer, cardiovascular disease, arthritis,
and other autoimmune diseases. In this mini-review, we discuss the latest advancements
in elucidating the function(s) of each of the Dectin-1 cluster CLRs, focussing on their
physiological roles and involvement in disease.
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Introduction
C-type lectin receptors (CLRs) play essential roles in immunity
and homeostasis [1]. Comprising a family of more than 1000 pro-
teins that each contain at least one C-type lectin-like domain,
CLRs have been placed into 17 groups based on their structure
and/or function. Originally named for their dependence on Ca2+
ions for carbohydrate recognition, many CLRs also possess con-
served residues within their C-type lectin-like domains, such as the
QPD (Gln-Pro-Asp) and EPN (Glu-Pro-Asn) motifs, which confer
specificity for galactose and mannose-containing carbohydrates,
respectively. However, CLRs can lack these components and still
recognise sugars, as well as broader repertoire of ligands such as
proteins and lipids [1].
The Dectin-1 cluster forms part of one subgroup of CLRs
(group V), which consists of seven structurally related receptors,
all with a single carbohydrate recognition domain, that are all
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encoded in the same locus in both the mouse and human genome
[2] (Fig. 1). The receptors in this cluster are of particular interest,
as they were the first signalling CLRs to be identified on myeloid
cells, and none appear to require calcium to recognise their lig-
ands. These receptors, which include MICL, CLEC-2, CLEC-12B,
CLEC-9A, MelLec, Dectin-1 and LOX-1 (ordered based on genomic
location), are involved in a broad range of physiological activi-
ties, from embryonic development to immunity. Importantly, the
knowledge we are gaining from these receptors is opening excit-
ing new possibilities for the diagnosis and treatment of disease.
This mini-review, an update on our previous review of the Dectin-1
cluster [2], is aimed to provide an overview of each of these recep-
tors, focusing on research published since 2016, highlighting the
recent advancements made uncovering their functions.
MICL
Myeloid inhibitory C-type lectin-like (MICL, CLEC-12A, CLL-1,
DCAL-2, KLRL-1), as the name suggests, is primarily expressed by
C© 2019 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
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Figure 1. The Dectin-1 cluster of C-type lectin receptors.
Shown is the genomic structure and transcriptional direc-
tion (arrows; blue = inhibitory CLR, red = activation CLR,
green = unknown) of the Dectin-1 cluster of C-type lectin
receptors found onhuman chromosome12. The structure of
themurineDectin-1 cluster onmouse chromosome6 is sim-
ilar (not shown). Also shown are selected ligands for each
receptor, as well as the relevant diseases and/or patholog-
ical conditions that have been associated with these CLRs.
The cellular expression profile for the human receptors is
also shown. AGE, advanced glycation end-products; AML,
acute myeloid leukaemia; BDCA, Blood dendritic cell anti-
gen; CD, cluster of differentiation; CRP, C-reactive protein;
DHN, 1,8-dihydroxynaphthalene; IHD, ischemic heart dis-
eases; MDS, myelodysplastic syndromes; Ox-LDL, oxidised
Low Density Lipoprotein; RA, rheumatoid arthritis.
myeloid cells, including granulocytes and monocytes in humans
andmice. MICL possesses an ITIM in its cytoplasmic tail, which can
recruit Src homology region 2 domain-containing phosphatase-1
(SHP-1) and SHP-2, and through this pathway negatively regu-
lates inflammatory cellular responses, including the respiratory
burst [2] (Fig. 2). MICL has been implicated in antibacterial
autophagy and in regulating antibacterial NK cell cytotoxicity as
well as cytokine production, DC migration across the blood brain
barrier, antigen cross-presentation, and possibly a role in DC mat-
uration [1–3].
Endogenous ligand(s) of MICL have been detected in various
mouse tissues such as the heart, lung, liver, spleen, and kidney,
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Figure 2. Representative signalling components utilized by the Dectin-1 cluster of C-type lectin receptors and selected cellular and immunological
functions. The PAC-Man shape indicates the carbohydrate recognition domain, and the cytoplasmic motifs present in each receptor are indicated.
Red arrows indicate cellular functions that are stimulated following receptor ligation while blue arrows indicate cellular functions that are
repressed following receptor ligation. Receptors have been ordered based on their genomic localisation. Detailed signalling pathways are not
shown. CARD, caspase recruitment domain-containing protein; NET, neutrophil extracellular traps; RAF, rapidly accelerated fibrosarcoma; Syk,
spleen tyrosine kinase.
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and recent studies show that this receptor senses dead cells [1, 2].
In fact, MICL recognises uric acid, a key danger signal for cell-
death-induced immunity and MICL-deficient mice exhibit hyper
inflammatory responses to necrotic cells. MICL-deficient mice also
present with enhanced joint inflammation during a collagen anti-
body induced arthritis model, implicating the inhibitory func-
tions of this receptor in the pathogenesis of rheumatoid arthri-
tis. Although there are no genetic alterations linked to disease in
humans, a subset of rheumatoid arthritis patients possess autoan-
tibodies to MICL, which are able to exacerbate disease [4].
There has been considerable interest in human MICL in acute
myeloid leukaemia (AML) andmyelodysplastic syndromes (MDS),
and this receptor represents a promising therapeutic and diag-
nostic target [5]. MICL is highly expressed on leukaemia stem
cells, but not on normal hematopoietic stem cells, and high lev-
els of MICL expression is correlated to poor prognosis [5, 6].
Immunotherapies for AML targetingMICL (including T cell recruit-
ing bispecific antibodies and chimeric antigen receptor T cells) are
being developed, and several are undergoing clinical trials [5].
CLEC-2
CLEC-2 (CLEC-1B) is expressed by platelets, megakaryocytes, and
to a lesser extent by B cells and myeloid cells, including neu-
trophils, macrophages and subsets of DCs and has been largely
studied in mouse models [1, 2]. Several ligands for CLEC-2 have
been identified including rhodocytin (a protein present in snake
venom), sulphated polysaccharides (such as fucoidan), diesel
exhaust particles, and podoplanin (a mucin-type glycoprotein),
although the biochemical basis underlying some of these inter-
actions is still unknown [1, 2]. CLEC-2 had been implicated in
recognition of HIV, but this recognition was subsequently shown
to be indirect, through viral incorporation of podoplanin. Like
other receptors in the Dectin-1 cluster, CLEC-2 possesses a hemi-
ITAM in its cytoplasmic tail that mediates intracellular signalling
though spleen tyrosine kinase (Syk)-dependent pathways (Fig. 2).
CLEC-2’s expression on platelets has generated interest in its
function in haemostasis and thrombosis. CLEC-2 plays a minor
role during normal haemostasis, facilitating platelet adhesion in
the vasculature, but under inflammatory conditions, it has a more
major role in preventing bleeding, although this may be organ
specific [7]. CLEC-2 is implicated in thrombosis, particularly dur-
ing inflammation, which causes upregulation of podoplanin on
stromal cells and macrophages [7, 8]. Interestingly, these activi-
ties of CLEC-2 appear to be independent of its ability to induce
intracellular signalling through the Syk pathway [9].
CLEC-2 is involved in development, cancer, and immunity. In
fact, CLEC-2 plays a critical role in embryonic development, facili-
tating blood-lymphatic separation, cerebrovascular patterning and
integrity, lymph node and lung development, as well as platelet
formation and the maintenance of hematopoietic stem cells in
the bone marrow [1, 2, 10]. In cancer, the interaction of CLEC-2
with podoplanin-expressing tumour cells promotes angiogenesis,
tumour growth and metastasis, and may represent a target for
therapy, if the side-effects on the haemostatic functions of the
receptor can be overcome [11]. In contrast, expression of CLEC-2
on some cancer cells, such as gastric cancer cells, may be protec-
tive [12].
CLEC-2 is involved in DC migration and in the lymph node
remodelling that is required for induction of adaptive immunity.
During inflammation, CLEC-2 can also regulate leukocyte recruit-
ment and activation, including adaptive responses, through inter-
actions with podoplanin expressed by these cells [13–15]. Despite
the considerable roles for CLEC-2 that have been gleaned from
mouse models, the direct involvement of this receptor in human
disease is yet to be described. However, plasma levels of soluble
human CLEC-2, presumably generated by protease cleavage, as
well as cellular expression levels are being explored as prognostic
indicators of disease outcome (such as acute ischemic stroke [16]
and cancer [17]).
CLEC-12B
By comparison with the other receptors in the Dectin-1 cluster,
CLEC-12B (Macrophage Antigen H, MAH) is poorly characterised.
Expression of a full length and spliced variant transcript, lack-
ing exon 4 (encoding part of the C-type lectin-like domain, and
presumably nonfunctional), was detected by RT-PCR in various
human organs; however, only heart, kidney, liver, lung, spleen,
and testis express the full length transcript [1, 2]. At the protein
level, CLEC-12B has been detected on the human monocyte cell
line, U937, following stimulation with phorbol 12-myristate 13-
acetate, but the expression patterns of this receptor on mouse and
human cells and tissues remain uncharacterised. CLEC-12B con-
tains a classical immunoreceptor tyrosine-based inhibition motif
in its cytoplasmic tail, that is able to recruit SHP-1 and SHP-2, and
was able to inhibit NK cell function when transduced into these
cells and following antibody crosslinking (Fig. 2).
Although its ligand(s) are unknown and its function is unde-
fined, CLEC-12B is thought to interact with caveolin-1. In the
context of disease, CLEC-12B is upregulated along with other
immunosuppressive genes during the transition from the acute
to asymptomatic stage during HIV infections, and it is part of a
set of negative regulators upregulated in Behc¸et’s Syndrome [18].
The presence of a polymorphism in CLEC12B, which may affect
the secondary structure of the C-type lectin-like domain, has been
linked in one family with predisposition to childhood cancer [19].
Suggestively, both SHP-1 and SHP-2 have also been linked to can-
cer, including melanomas, but more work is required to define the
physiological role of CLEC-12B.
CLEC-9A
CLEC-9A (DNGR-1) is an endocytic receptor which recognises
dead cells through exposed F-actin, a process which is enhanced
by myosin II [20]. In humans, CLEC-9A is expressed on immature
BDCA3+ DCs and on a small subset on CD14+CD16- monocytes,
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and in the mouse, on CD8α+ conventional DC and plasmacytoid
DCs. In fact, the expression profile of CLEC-9A has promoted its
use both as a cellular marker and lineage tracer.
Structurally, CLEC-9A is very similar to Dectin-1, containing
a hem-ITAM in its cytoplasmic tail that is able to induce intra-
cellular signalling through Syk kinase (Fig. 2). Unlike Dectin-1,
however, CLEC-9A does not appear to trigger cellular activation;
rather induction of this signalling pathway promotes antigen cross-
presentation to CD8+ T cells through a poorly defined mecha-
nism involving pH-dependent conformational changes of the neck
region of the receptor [21]. The cross-presentation activities of
CLEC-9A have been shown in mice to be required for promoting
protective CD8+ T cell responses to some (e.g. vaccinia virus,
HSV), but not all (e.g. RSV), viral infections [1]. Notably, the abil-
ity of CLEC-9A to promote cross-presentation has prompted con-
siderable interest in antigen targeting to this receptor to increase
efficacy of cancer immunotherapies and vaccines [22].
Very recently, CLEC-9A has been discovered to restrict neu-
trophil recruitment during inflammation to limit tissue damage
[23]. In mouse models of caerulein-induced necrotizing pancre-
atitis and systemic Candida albicans infection [23], activation of
CLEC-9A by the cell death that occurred during inflammatory
responses inhibited the production of the neutrophil-recruiting
chemokine, MIP-2. Unexpectedly, this activity was found to be
mediated through the recruitment of the inhibitory phosphatase,
SHP-1, to the cytoplasmic tail of CLEC-9A (Fig. 2). The ability of
CLEC-9A to limit neutrophil recruitment has also been observed
in a mouse model of Mycobacterium tuberculosis infection [24]. In
addition, there is also evidence from mice for involvement of this
receptor in the regulation of inflammation during atherosclero-
sis [25]. As yet, there is no link between CLEC-9A and any human
disease.
MelLec
Melanin sensing C-type Lectin receptor (MelLec, CLEC-1, CLEC-
1A) was identified nearly two decades ago and is broadly
expressed by endothelial cells in humans, mice, and rats. In
humans and rats, this receptor is also expressed on myeloid cells,
including various DC populations, monocytes, macrophages, and
granulocytes [26]. MelLec was recently shown to recognise 1, 8-
dihydroxynaphthalene melanin, an immunologically active com-
ponent found in the cell wall ofmelanised fungi, such as Aspergillus
fumigatus [27]. In mice, loss of MelLec led to decreased survival
and increased fungal burdens in a systemic model of A. fumigatus
infection through a delay in neutrophil recruitment [27]. Consis-
tent with this observation, a polymorphism in the cytoplasmic tail
of MelLec was associated with increased susceptibility to dissemi-
nated Aspergillus infections in stem-cell transplant patients [27].
MelLec has also been implicated in modulating T cell func-
tion [26]. In rats, the absence of MelLec led to exacerbated Th17
responses, which correlated with enhanced IL-12p40 expression
by DCs [26]. Notably, decreased MelLec expression in human lung
transplants was associated with increased levels of IL-17A and
chronic rejection [26]. Similar findings were also observed in rat
allograft models. This suggests that MelLec may play a role in
the tolerogenic response to allografts, through recognition of an
unknown endogenous ligand [26]. HowMelLec mediates its phys-
iological functions is still unknown, although the receptor contains
a YSST and tri-acidic DDD motif in its cytoplasmic tail that could
potentially mediate intracellular signalling [2] (Fig. 2).
Dectin-1
Dectin-1 (CLEC-7A) is one of the best characterised CLRs in
mice and in humans and is predominantly expressed on myeloid
cells, including monocytes, macrophages, dendritic cells, and neu-
trophils [28]. Dectin-1 is also expressed by B cells in humans and
by some subsets of T cells [1]. There is also some evidence for
expression on other cell types, including epithelial cells [1, 29].
There are two major isoforms of Dectin-1 (one of which lacks the
stalk region), and these show cell (and mouse strain) specific pat-
terns of expression. Dectin-1 recognises β-glucans, carbohydrates
commonly found in the cell walls of plants and fungi, but has
also been reported to recognise tropomyosin (found in arthro-
pods) and unidentified ligand(s) in mycobacteria and Leishma-
nia [28, 30, 31]. Several endogenous ligands have also been iden-
tified including vimentin, galactosylated immunoglobulins, and
galectins [28, 32].
Ligand recognition by Dectin-1 triggers intracellular signalling
through a hem-ITAM in the cytoplasmic tail of the receptor
that induces multiple downstream pathways, including Raf-1 and
Syk/CARD9 (Fig. 2). Signalling from Dectin-1 can induce or regu-
late numerous cellular responses, including phagocytosis, the res-
piratory burst, neutrophil extracellular trap formation, autophagy,
DC maturation and antigen presentation, inflammasome acti-
vation (including the NLRP3 and the non-canonical caspase-8
inflammasomes), and the production of eicosanoids, cytokines,
and chemokines [28]. Dectin-1 is also capable of modulating the
cellular responses induced by other pathogen pattern recogni-
tion receptors, can directly induce innate immune memory, and
influence the development of CD4 and CD8 T cells and B cell
responses [1, 33, 34].
Dectin-1 has been most studied in the context of anti-fungal
immunity usingmousemodels. Indeed, through its ability to recog-
nise β-1,3-linked glucan, Dectin-1 is required to drive protec-
tive host responses to many pathogenic fungal species, including
Aspergillus, Candida, Pneumocystis, although its involvement may
depend on particular strains of these organisms. Importantly, in
humans, polymorphisms of Dectin-1 are associated with increased
susceptibility to fungal disease [28]. The functions of Dectin-1 are
also important for maintaining gastrointestinal homeostasis and
can exacerbate the severity of colitis, through recognition specific
fungi in the microbiota as well as food derived β-glucans [35–37].
Interestingly, Dectin-1 responses have been implicated in the
pathogenesis of obesity [38] and alcoholic liver disease, following
intestinal release of fungal β-glucans into the bloodstream [39].
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More recently, Dectin-1 has been implicated in allergy and
cancer. Although Dectin-1 is known to promote Th1 and Th17
immunity, this CLR can also drive Th2 responses, in part through
the production of prostaglandin E2 [33]. Indeed, through this and
other pathways, including regulation of IL-22 and IL-33, Dectin-
1 has been linked to the pathology of allergic responses in both
mouse models and in humans [30, 40]. Dectin-1 has dual func-
tions in cancer, either promoting or preventing oncogenesis. For
example, in pancreatic ductal adenocarcinoma, Dectin-1-mediated
recognition of tumour-associated Galectin-9 supresses protective
T cell responses [32]. In contrast, Dectin-1-mediated recognition
of N-glycan structures on tumour cells can lead to activation of the
tumoricidal activities of NK-cells. Dectin-1 can also mediate pro-
tective activities by supressing TLR4-mediated inflammation and
by promoting Th9 immunity [1, 34].
LOX-1
Lectin-like oxidised low density lipoproteins (LDL) receptor-1
(LOX-1, OLR-1, CLEC-8A) is expressed on endothelial cells but
also by a variety of other cell types including leukocyte pop-
ulations (such as macrophages, monocytes, DCs, and B cells),
smooth muscle cells, neurons, and fibroblasts [41]. Although
normally expressed at low levels, in part through regulation by
casein kinase 2-interacting protein-1 [42], LOX-1 is rapidly upreg-
ulated by a variety of factors, particularly pro-atherogenic stim-
uli including inflammatory cytokines and modified LDL. LOX-1
can be cleaved by ADAM10 proteases to produce a soluble form
(sLOX-1) than is detectable in the serum, and N-terminal frag-
ments that remain bound in the membrane [43]. LOX-1 is able to
recognise a broad range of ligands including bacterial products,
C-reactive protein, and advanced glycation end products, but is
best known for its ability to bind oxidised LDL (ox-LDL). LOX-1
can internalize its ligands through a cytoplasmic tripeptide (DDL)
motif, and induce intracellular signalling that results in a variety
of cellular responses including the production of ROS, chemokines
and cytokines, upregulation of adhesion molecules, apoptosis, as
well as activation of the NALP3 inflammasome and NF-κB [44].
How LOX-1 mediates intracellular signalling is unclear, but recent
evidence implicates the membrane N-terminal fragments in these
activities, and their regulation by the signal peptide peptidase–like
2a and b (SPPL2a/b) [43].
LOX-1 has been extensively studied in the context of atheroscle-
rosis and associated vascular diseases, including hypertension and
stroke. Indeed, data from mouse models has convincingly demon-
strated the role of LOX-1 in numerous pro-atherogenic activities
includingmacrophage foam cell and plaque formation, endothelial
dysfunction (such as increased ROS leading to activation of NF-κB
and induction of adhesion molecules and apoptosis), proliferation
of vascular smooth muscle cells, platelet aggregation, and leuko-
cyte recruitment [41]. Notably, in humans, polymorphisms and
alternative splice variants of LOX-1 gene are associated with either
promotion or protection from disease [45]. Moreover, the levels of
sLOX-1 can be used as a prognostic and diagnostic marker for car-
diovascular disease, and possibly stoke, in patients [41, 44, 46].
Given its detrimental activities, there is considerable interest in
developing novel therapeutics that target LOX-1. Several drugs
already in clinical use for treating cardiovascular disease appear
to affect LOX-1, including statins, which disrupts LOX1-mediated
recognition of oxLDL [41].
In the immune system, LOX-1 is able to regulate inflammatory
responses to bacterial (including sepsis) and fungal pathogens. In
fact, there is emerging evidence from mouse models that LOX-1
may represent a therapeutic target to treat Aspergillus-mediated
keratitis [47]. LOX-1 is also involved in antigen cross-presentation
(in part through the recognition of dead cells) and can promote
B cell differentiation and antibody class switching. Moreover, tar-
geting LOX-1 can promote antigen-specific T cell responses [48].
LOX-1 is involved in the pathophysiology of arthritis and can-
cer. In mouse models of arthritis and osteoarthritis, deletion of
LOX-1 (which is upregulated on chondrocytes and other cells in
affected joints) was shown to protect against disease [49, 50]. In
humans, sLOX-1 has been proposed as a biomarker for diagnosis
and evaluation of disease activity. Changes in lipid metabolism are
associated with oncogenesis, and the activities of LOX-1 (which is
upregulated in a wide range of cancers) in this context have been
linked to promoting the development of cancer, including angio-
genesis, tumour invasion, and metastasis [51]. Expression levels
of LOX-1 have been proposed to have prognostic and therapeutic
potential [52, 53].
Conclusion
Receptors of the Dectin-1 cluster have a wide range of func-
tions and are involved in numerous diseases. In the last two
decades, many important discoveries have been made regarding
these receptors that have therapeutic implications. Indeed, char-
acterisation of their structures, the identification of their ligands,
and their signal transduction pathways has already led to new
prognostic and diagnostic markers and novel immunotherapeu-
tic approaches. It will be exciting to see how our ever-expanding
knowledge of this C-type lectin subfamily is used to tackle disease
in the future.
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